Cipher Pharmaceuticals (TSE:CPH) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR)’s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CPH shares. Stifel Nicolaus cut their price target on Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday, November 11th. Leede Financial downgraded Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Price Performance

The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average price is C$14.60 and its 200-day moving average price is C$14.02. The stock has a market capitalization of C$377.20 million, a PE ratio of 11.79 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). The company had revenue of C$14.15 million for the quarter, compared to analysts’ expectations of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. On average, equities analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.